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Sir,
The wide mutational spectrum found in cystic fibrosis (CF;
OMIM 219700; http://www.genet.sickkids.on.ca) is a perma-
nent challenge that needs specific approaches in each
population. Currently, CFTR genetic testing is performed
applying commercial panels and/or sequencing (directly or
after scanning techniques) [1]. However, once the mutation has
been characterized, a specific method is usually developed
(heteroduplex analysis, Taqman probe, RFLP, etc.) to facilitate
its detection in further studies concerning a family and/or a
particular population.
Among 250 mutations characterized in the Spanish CF
population [2,3] three have been found close together in exon
10, p.Phe508del (F508del; 52%), p.Ile507del (I507del; 1%) and
c.1545_1546delTA (1677delTA; 0.1%). In addition to patients/
families bearing one of these mutations, we have identified nine
compound heterozygous patients (6 p.Phe508del/p.Ile507del; 2
p.Phe508del/c.1545_1546delTA; and 1 p.Ile507del/
c.1545_1546delTA).
A previous protocol [4] was modified to offer cascade carrier
testing. Briefly, the PCR conditions were, denaturation (94°C/
3 min), 30 cycles 94 °C/20 s, 62 °C/30 s, 74 °C/30 s and
extension (74 °C/5 min) followed by electrophoresis on an
8% polyacrylamide gel (PAGE; 20×20cm) for 4 h at 160 V and
ethidium bromide staining.
Nine DNAs from different sources were analysed to evaluate
whether the patterns in heterozygous, homozygous and
compound heterozygous individuals could be discriminated.
The different genotypes differed by 0–3 base pairs (Fig. 1).
Homozygous p.Phe508del, homozygous p.Ile507del and com-
pound heterozygous p.Phe508del/p.Ile507del (# 1,3,5) showed
the same profile as both mutations determine the deletion of
Journal of Cystic Fibrosis 1Fig. 1. Direct analysis of three CF-causing mutations in exon 10. PCR primers: C16B
CTT TGA TGA CGC TTC-3′ [4]. WT, wild type; NTC, no template control; HT, het
p.Phe508del; 2, p.Phe508del/c.1545_1546delTA (1677delTA); 3, p.Ile507del/p.Ile
c.1545_1546delTA; 7, p.Phe508del/wt; and 8, p.Ile507del/wt.
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doi:10.1016/j.jcf.2010.11.002three base pairs and in this case the heteroduplex bands were
indistinguishable from the homoduplex. Among the other
samples, six specific patterns were observed, one wild type,
three heterozygous samples (# 4,7,8) and 2 compound
heterozygous (# 2,6). Interestingly, visualization of the hetero-
duplex bands was found to be as important as homoduplex for
assigning each genotype.
Given the specific mutation patterns, the analysis was applied
to a high risk couple who requested a prenatal diagnosis. DNAs
were extracted from blood leukocytes (parents), dried blood spot
(index case with genotype p.Phe508del/c.1545_1546delTA)
and the chorionic villus sample. PCR products were detected in
all the samples. The foetal and the paternal samples showed the
c.1545_1546delTA heterozygous pattern. As recommended [1],
maternal contamination was discarded analysing two micro-
satellite markers, IVS8CA and IVS17bTA (data not shown).
Maximizing test efficiency in target populations
The c.1545_1546delTA reaches high frequencies in specific
populations. Particularly, it has been reported in Russia (0.8%)
[5], Greece (0.9%) [6], Bulgaria (2.4%) [7] and Turkey (7.2%)
[8]. In contrast, the p.Ile507del mutation has not been detected
either in Bulgaria or in Turkey. Overall, the analysis of the three
mutations accounts for 30.7% of CF alleles in Turkey, 55.0% in
Greece and Russia and 67.8% in Bulgaria.
For these mutations, discrepancies and misinterpretation of
genotypes have been reported for commercial panels [9].
Here, we propose an easy method for the suitable detection
of three nearby CF-causing mutations facilitating the CF
molecular diagnosis in those populations in which the mutations
are prevalent and reducing the number of samples for further
more expensive mutation panels. For the three undistinguished
patterns, the analysis of the CF parents would be determinant as
each mutation to be detected shows a specific pattern in, 5′-GTT TTC CTG GAT TAT GCC TGG CAC-3′; C16D, 5′-GTT GGC ATG
eroduplex; PAGE, polyacrylamide gel electrophoresis. Samples: 1, p.Phe508del/
507del; 4, c.1545_1546delTA/wt; 5, p.Phe508del/p.Ile507del; 6, p.Ile507del/
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144 Letter to the Editorheterozygous samples. This accurate analysis could be applied
to the cascade carrier testing and prenatal diagnosis, as well as
in the flowchart for CF diagnostic testing in particular
populations. Furthermore, the strategy might be advantageous
in other genetic disorders showing mutations with similar
characteristics. In summary, we propose joining old and new
technologies to achieve a rational optimization of the available
resources.
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